

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934

Date of Report (Date of earliest event reported)
August 31, 1995

Amgen Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-12477	95-3540776
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1840 Dehavilland Drive, Thousand Oaks, California 91320-1789

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code
(805) 447-1000

(Former name or former address, if changed since last report)

Item 5. OTHER EVENTS

Amgen Inc. (the "Company") and one of its licensees, Ortho Pharmaceutical Corporation, a subsidiary of Johnson & Johnson ("Johnson & Johnson"), are parties to an arbitration proceeding described in the Company's Form 10-K for the year ended December 31, 1994 and the Company's Form 10-Q for the period ended June 30, 1995. On August 31, 1995, the Company

filed a demand in the arbitration seeking: (1) termination of the product license agreement between the Company and Johnson & Johnson, (2) an accounting of Johnson & Johnson's spillover sales and (3) damages. The Company is unable to predict at this time the outcome of this demand or when it will be resolved.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amgen Inc.

(Registrant)

September 1, 1995

(Date)

/s/ Robert S. Attiyeh

(Signature)

Robert S. Attiyeh
Senior Vice President
Finance and Corporate Development,
and Chief Financial Officer